U.S. pharma giant copyright scrapped two experimental weight loss tablets final 12 months—a once-everyday capsule, lotiglipron, on account of elevated liver enzymes in addition to a twice-day by day tablet, danuglipron, as a result of powerful side effects—but CEO Albert Bourla has said the company is decided to “play and gain” within the b